"Mount Sinai And Theragene Collaborate To Develop New Gene Therapy For Pulmonary Hypertension" - Irena Ilic, MD
Researchers from Mount Sinai have partnered with Theragene Pharmaceuticals to further develop a new airway-delivered gene therapy for pulmonary hypertension (PH). After showing promising results in animal studies, this new therapy will advance to clinical trials, which are expected to take place in the next two years. “PH is a devastating disease, and our work in collaboration with many laboratories across the country has allowed us to identify a specific molecular target and use gene therapy to improve cardiovascular and lung parameters in experimental models of PH,” said senior author Roger Hajjar, MD, professor of medicine and cardiology at the Icahn School of Medicine at Mount Sinai. This gene therapy option represents a critical advancement in PH treatment, added Dr. Hajjar.
- Roger Hajjar, MD, Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai